Suppressive oral acyclovir for six months after neonatal herpes targets ongoing viral activity that can cause recurrent mucocutaneous lesions and, more importantly, potential CNS damage. By keeping viral replication in check during this early period, recurrences are reduced and the risk of neurodevelopmental impairment diminishes, leading to better developmental outcomes. It doesn’t raise risk for bacterial infections, isn’t unnecessary for infants with neonatal HSV, and neutropenia is not a typical outcome of this regimen. The main benefit is fewer recurrences and improved neurodevelopmental prognosis.

When a young child avoids school or fakes illness, the most useful first question is to invite them to name one or two friends at school. This taps directly into their social world, which is a major driver of how they feel about attending class at this age. If they can easily identify friends, it suggests they have at least some peer support and a positive social anchor, which can buffer distress and guide you toward understanding how those relationships affect their school experience. It also opens a natural, non-threatening path to explore social dynamics—like whether they feel included or if a particular peer interaction is bothering them—without forcing discussions about academics or discipline right away. Asking about friends is more developmentally appropriate and approachable for a 6-year-old than jumping straight to grades or trying to parse the reasons school is distressing. Inquiries about grades don’t yield meaningful information at this age, since formal performance metrics aren’t the same as in older students. Directly probing why school is distressing can come next, once you’ve established who their support network is and whether they have peers they trust. Asking about bullying is important too, but starting with naming friends quickly reveals whether social connections exist and can set the stage for deeper questions about safety and peer interactions.

Early intervention for children under three is organized through an individualized family service plan (IFSP) that coordinates services in the child’s natural environment. Asking the family whether they already have an IFSP is the natural first step because it quickly shows whether there is an existing plan to build on and what services are already in place or needed. If an IFSP exists, you review it and help connect the family with the listed services and goals. If there isn’t one, you begin the evaluation and eligibility process to establish an IFSP and arrange appropriate supports in the home or community. School-based services or IEPs are not the starting point for a child under three; they come into play later, typically when the child enters preschool or kindergarten. While referrals to a social worker or physician involvement can be part of coordinating care, the initial action should be to determine the status of an IFSP and initiate or update the plan accordingly.

Pityriasis rosea usually begins with a herald patch—an oval, salmon-colored patch that appears on the trunk or proximal limbs. This single patch often goes noticed at first, but it signals the start of the classic course: a secondary eruption that follows a Christmas-tree pattern on the back and chest. The condition is typically self-limited and not contagious, facial involvement is uncommon, and severe itching is not the defining feature (pruritus, if present, is usually mild to moderate). So the herald patch is the hallmark feature that best fits pityriasis rosea.

Broader serotype coverage in pneumococcal vaccines reduces disease more effectively. PCV7 protected seven pneumococcal serotypes, but disease caused by non-covered serotypes persisted, and strains like 19A became more common and sometimes harder to treat. To broaden protection, a newer vaccine that includes more serotypes was developed, and in 2010 health authorities recommended substituting this 13-valent vaccine for PCV7 in the routine pediatric vaccination schedule. This 13-valent formulation adds several serotypes not present in PCV7, expanding protection against invasive pneumococcal disease in children. The other option is not the standard pediatric replacement in 2010: the 23-valent polysaccharide vaccine is used mainly in adults and some high-risk groups, not as the primary pediatric series. The older vaccine is PCV7, and PCV33 isn’t part of the licensed pediatric vaccines. So, the vaccine that replaced PCV7 in 2010 is PCV13.